Update on pulmonary hypertension
Abstract
The hemodynamic definition of pulmonary hypertension including a mean pulmonary arterial pressure > 20 mmHg is evidence based, but the threshold of 15 mmHg for the pulmonary arterial wedge pressure, deciding between pre-and postcapillary PH, is not. Indeed, based on the most recent literature, the normal PAWP is ≤ 13.0 mmHg, raising some interesting questions. The TASK Force on treatment of pulmonary arterial hypertension (PAH) at the latest world symposium for pulmonary hypertension published a new therapeutic algorithm for PAH that looks simpler than the previous algorithm. However, this algorithm exclusively refers to high-quality evidence from pivotal studies. Sildenafil appears to be safe and effective up to 80 mg TID, combination pills including macitentan and tadalafil are available. The activin signaling inhibitor sotatercept has changed our way of thinking about PAH therapy due to unprecedented efficacy. It is highly efficacious not only in WHO FC 2–3 but also in WHO FC 4 PAH. However, according to the recent literature, the long-term effects include systemic and pulmonary microvascular malformations. The serotonin-, tyrosine kinase-, estrogen, and carboanhydrase pathways have successfully been targeted in several PH models and showed excellent safety profiles in early clinical development. However, the approval-oriented clinical studies, published in high-ranking journals, have only met their primary endpoint in case of inhaled seralutinib and inhaled MK5475. Group…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.